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Abstract The increased use of genomic sequencing in clini-
cal diagnostics and therapeutics makes imperative the devel-
opment of guidelines and policies about how to handle sec-
ondary findings. For reasons both practical and ethical, the
creation of these guidelines must take into consideration the
informed opinions of the lay public. As part of a larger
Clinical Sequencing Exploratory Research (CSER) consor-
tium project, we organized a deliberative democracy (DD)
session that engaged 66 participants in dialogue about the
benefits and risks associated with the return of secondary
findings from clinical genomic sequencing. Participants were
educated about the scientific and ethical aspects of the disclo-
sure of secondary findings by experts in medical genetics and
bioethics, and then engaged in facilitated discussion of policy
options for the disclosure of three types of secondary findings:
1) medically actionable results; 2) adult onset disorders found
in children; and 3) carrier status. Participants’ opinions were
collected via surveys administered one month before, imme-
diately following, and one month after the DD session. Post
DD session, participants were significantly more willing to
support policies that do not allow access to secondary findings
related to adult onset conditions in children (Χ2 (2,
N = 62) = 13.300, p = 0.001) or carrier status (Χ2 (2,
N = 60) = 11.375, p = 0.003). After one month, the level of
support for the policy denying access to secondary findings
regarding adult-onset conditions remained significantly higher
than the pre-DD level, although less than immediately post-
DD (Χ2 (1, N = 60) = 2.465, p = 0.041). Our findings suggest
that education and deliberation enhance public appreciation of
the scientific and ethical complexities of genome sequencing.
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Introduction
At present, genomic sequencing—ranging from targeted sin-
gle gene assays and mutation panels to genome-scale tests
such as tumor whole-exome sequencing—is used as a cost-
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effective alternative to performing multiple diagnostic tests as
well as to aid in the diagnosis, treatment, and prevention of
genetic conditions not identifiable through conventional mo-
lecular testing (Van Allen et al. 2013). The goal of integrating
genomic sequencing into clinical practice has been, and will
increasingly be, to improve how we diagnose and treat dis-
eases. However, this technology also raises complex scientif-
ic and ethical issues regarding the disclosure of sequencing
results including those secondary to the clinical indication for
ordering the test (McGuire et al. 2013; Wolf et al. 2013).
While secondary findings are often of clinical significance,
they also can reveal a wide range of health-related conditions
where significance is unknown, or further screening or treat-
ments may not exist, creating unintended psychological, so-
cial, and medical consequences (Christenhusz et al. 2013;
Johnston et al. 2012; Kohane et al. 2012; Shkedi-Rafid
et al. 2014). As genomic sequencing becomes a standard part
of clinical diagnostics, it is imperative that guidelines and
policies about how to handle secondary findings be
developed.
In an effort to provide guidance on the management of
secondary findings, genetic researchers and health profes-
sionals’ views have been studied (Appelbaum et al. 2015;
Grove et al. 2014), advisory panels have been convened
(Green et al. 2013), and the Presidential Commission for the
Study of Bioethical Issues has provided input (Weiner 2014).
In addition, the American College of Medical Genetics and
Genomics has published an official guideline and a recom-
mendation, both of which became sources of controversy
within the field as experts debated the extent to which labora-
tories and clinicians are obligated to report secondary find-
ings, and the conditions under which patients should be able
to opt in or out of receiving such results (ABIM Foundation
2015; ACMG Board of Directors. 2015; American College of
Medical Genetics and Genomics 2013; Green et al. 2013;
Scheuner et al. 2015). As a result, there is no clear consensus
on how to guide policy regarding the disclosure of secondary
findings.
As experts work towards shaping a national policy, it is
also important to take into consideration public viewpoints.
The aforementioned debate on the appropriate management
of secondary findings from genomic sequencing has not
included a high level of public engagement with key stake-
holder groups. The issues that surround the return of sec-
ondary findings are not exclusively scientific in nature, but
are also rooted in concerns regarding the public’s values
and preferences.
Results of previous research on patient preferences
regarding disclosure of secondary findings are inconsis-
tent. Some studies found that members of the public
want unrestricted access to their genetic information,
even after a comprehensive discussion with a health
professional (e.g. genetic counselor) (Bollinger et al.
2012; Facio et al. 2013; Kaufman et al. 2008). Other
studies suggest that awareness of the potential complex-
ities of testing may shift towards more conservative
preferences for genomic sequencing and secondary in-
formation. For example, a recent study found that ge-
netic health professionals, who have extensive knowl-
edge and experience with genetic testing, exhibit less
desire to learn secondary findings regarding genetic
risks for developing serious and preventable conditions
relative to laypeople (Middleton et al. 2015). Another
study found that among a group of breast cancer pa-
tients who received genetic counseling, approximately
30 Q declined multiplex gene panel testing due to con-
cern about the uncertainty of the results and utility of
the information (Bradbury et al. 2015). Additionally, a
recent study of three focus groups with individuals who
had prior preconception genetic testing experience dem-
onstrated different perceptions of the advantages or dis-
advantages of screening within each group, suggesting
tailored approaches to education, consent, and counsel-
ing may be warranted (Schneider et al., 2016). Another
focus group on genetic testing involving children
highlighted concerns about the return of secondary find-
ings only because of the discussion that occurred in a
group context (Christenhusz, Devriendt, Peeters, Van
Esch, & Dierickx, 2014). Policy issues related to the
disclosure of secondary findings resulting from genomic
sequencing involve complex scientific, regulatory, and
ethical considerations. The extent to which respondents
in these studies considered such complexities prior to
articulating their preferences is not known.
Collectively, these studies suggest that simply receiving
information about the risks and benefits of genomic testing
seems to increase the desire of the lay public to receive
secondary findings, while more in-depth knowledge of
the complexities of genomic testing, together with group
interactions, may modify these views. Further, while these
studies highlight shifts in personal preferences for receiv-
ing secondary findings, it is unclear what laypeople think
public policy should be regarding the disclosure of second-
ary findings. Finally, the findings of these studies also under-
score that soliciting “public opinion” on issues of health pol-
icy cannot be equated with soliciting “informed public opin-
ion”, as greater knowledge or dialogue seems to temper pref-
erences for receiving secondary findings. Assuming that an
informed person provides a more ideal measure of prefer-
ences, we should seek to solicit informed public opinion when
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crafting public policies (Fishkin, 2006; Kim, Wall, Stanczyk,
& De Vries, 2009).
One mechanism for the study of informed public opinion is
democratic deliberation (DD). This approach begins by edu-
cating members of the public on a given topic using presenta-
tions delivered by experts with diverse opinions in the field;
participants then engage in small group discussions about the
issues, after which their informed and collectively considered
opinions are solicited, often through a vote (Fishkin, 2006;
Gastil & Keith, 2005; Thompson, 2008). Previous research
using DD found shifts in policy preferences and demonstrated
that these shifts are not only attributed to participants simply
being informed, but also from engaging with one another
about the complexities of the issues (Kim et al., 2011). DD
methodology has gained traction in bioethics, having been
used to elicit public views on cancer screening and consent,
biobank development, and surrogate consent for research in-
volving persons with dementia (Kim et al., 2011; McWhirter
et al., 2014; Rychetnik et al., 2013; Thomas et al., 2014).
As part of a larger research project (MI-ONCOSEQ)
(Roychowdhury et al., 2011) that is integrating somatic and
germline sequencing and analysis into clinical oncology prac-
tice and examining the psychosocial and ethical issues related
to disclosure of genomic results, we conducted a mixed
methods DD study between July 2014 and February 2015.
The goal of our DD study is to help inform national policy
on the disclosure of secondary findings by assessing the in-
formed, well-considered views of the lay public.
Materials and Methods
Study Design and Recruitment
Participants took part in a day-long DD session comprising of
educational presentations and facilitated small group discus-
sions. Additionally, they completed three surveys. Survey 1
was administered 1 month prior to the session. Survey 2 was
completed immediately following the session. Survey 3 was
administered 1 month after the session.
We recruited participants through the University of
Michigan Clinical Studies website, a voluntary partnership
created for patients and community members to find clinical
and health research studies at the University of Michigan
[http://UMClinicalStudies.org]. This website is a secure,
password-protected recruitment portal that assists researchers
in identifying, recruiting, and retaining study participants.
Study teams provide basic information about their studies in-
cluding, purpose, eligibility, what participation involves, and
contact information. Potential volunteers visit the website and
can sign up for a single study or for a general registry. From
this convenience sample, individuals who expressed interest
in the study were asked a series of screening questions on age,
gender, ethnicity, and personal history of cancer to ensure
diversity both in sample characteristics and diversity in partic-
ipant health related experience. Participants had to be at least
21 years of age. Due to the focus of the MI-ONCOSEQ pro-
ject on integrating genomic testing into clinical cancer care,
we enrolled 38 participants with a personal history of cancer –
as indicated in their UM Clinical Studies profile – and 38
without such a reported history. This study was deemed ex-
empt from federal regulations by the University of Michigan’s
Institutional Review Board.
Procedures
One month prior to the DD session, participants were mailed
Survey 1 along with an informational brochure (Brochure S1)
and glossary of genomic sequencing terms (Glossary S2) to
ensure that all participants had a basic level of understanding
of genomic sequencing terminology. The brochure and glos-
sary were developed by the study team and reviewed by an
advisory panel consisting of an expert in DD methods, a se-
nior genetics researcher in adult-onset disorders, a bioethicist-
sociologist, a pediatrician, a qualitative research expert, and a
genetic counselor. These materials were further refined, based
on a final systematic review by the members of the advisory
panel, additional external experts (in both genetics research
and bioethics), and laypersons.
Participants attended a day-long DD session modeled on
formats used in prior DD sessions (Kim et al., 2011; Kim
et al., 2009) (Table 1). Participants were assigned to one of
ten groups, each comprised of 6 to 8 participants. The groups
were organized into three categories: participants with a per-
sonal history of cancer (3 groups), participants without a per-
sonal history of cancer (3 groups), and mixed (4 groups). We
oversampled participants with personal and family histories of
cancer because a significant proportion of secondary findings
from genomic sequencing that are medically actionable per-
tain to cancer risk, and therefore policies in this area are likely
to be particularly salient for this subgroup (ACMG Board of
Directors, 2015). A trained facilitator moderated the discus-
sion at each table. Each facilitator had a background in either
genetic counseling or health education and received two hours
of DD facilitator training from a study team investigator with
expertise in qualitative research and in the conduct of DD
sessions, consistent with training procedures for other pub-
lished studies using this methodology (Kim et al., 2009).
Experts and members of the study teamwere available to field
questions that emerged during the small group discussions
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throughout the day. At the end of the session, attendees were
asked to complete Survey 2. The follow-up survey (Survey 3)
was administered one-month following the session.
Participants received $150 for attending the session and com-
pleting all three surveys.
DD Session PresentationsWe developed two 35-min educa-
tional presentations. The first, entitled “What can we learn
from sequencing our genes?” described the science and tech-
nology behind genomic sequencing. The second, “Ethical is-
sues in sequencing our genes,” offered an introduction to the
bioethical issues that attend genomic medicine. The presenta-
tions were developed using an iterative process between study
team members, the advisory panel, and the expert presenters;
among the goals was to provide our DD attendees with a
balanced presentation of the pros and cons and benefits and
risks of this new technology in an effort to minimize bias to
the best of our ability. These two presentations were followed
by an explanation of proposed policies regarding the return of
secondary findings when these findings revealed medically
actionable results, adult-onset conditions, and carrier status
(Table 1).
Small Group Voting In their small groups, participants were
asked to discuss, and then vote on, the proposed policy for
each of the three situations. The question they were asked was,
“Should this be the genomic sequencing policy regarding the
return of secondary findings with information about [medical-
ly actionable conditions/adult-onset conditions/carrier sta-
tus]?” The main purpose of the voting was to enhance discus-




The study team developed the three surveys (baseline, post-
deliberation, and follow-up) based on a literature review and
an iterative process between the advisory panel and study team
members (Table 2 and Survey S3).
Survey 1: Baseline assessment
Attitudes towards Proposed Policies Participants were
asked to reflect on three proposed policies for the return of
secondary findings identified through genomic sequencing.
The policies were based on a review of the literature and
Table 1 Overview of DD session
Plenary Introduction Overview of the agenda for the day
Small Group: Session 1 Ice breaker exercises
Video, “Whole Genome Sequencing and You”a Discussion focusing
on reactions to the video
Expert Presentations Each presentation lasted 50 min, including a 15 min question and answer session.
Presentation 1: “What can we learn from sequencing our genes”
Presentation 2: “Ethical issues in sequencing our genes”
Small Group: Session 2 Participants were given a chance to reflect upon and discuss the 2 presentations
and general thoughts on genomic sequencing. (30 min)
Policy Presentation Explanation of proposed policies regarding return of secondary findings in
3 situations – medically actionable results, adult-onset conditions, and
carrier status. For each policy, participants were asked to consider “Should this be
the genomic sequencing policy?”
Small Group: Session 3 Discuss & vote on proposed policy: “Patients are given medically actionable results
that are not related to the reason for the sequencing. Patients have a choice: They can ask
to NOT be given these results.” (30 min)
Small Group: Session 4 Discuss & vote on proposed policy: “Children and their parents are not given results for
adult-onset conditions that are not related to the reason for the sequencing. Children and
their parents have no choice: They will not be given these results even if they
want them.” (30 min)
Small Group: Session 5 Discuss & vote on proposed policy: “Patients are not given carrier status results that
are not related to the reason for the sequencing. Patients have no choice: They will
not be given these results even if they want them.” (30 min)
a © 2015 Icahn School of Medicine at Mount Sinai
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current medical practice. The survey included proposed poli-
cies for 1) medically actionable results; 2) childhood disclo-
sure of adult-onset conditions to parents; and 3) carrier status
for autosomal recessive conditions. The first part of each pol-
icy presented the default disclosure procedure according to
current standards of care in genetic medicine (e.g., whether
the results would be identified and returned to patients) and
the second part outlined whether the default position was flex-
ible (e.g., whether patients have a choice about whether they
could receive or decline information about secondary find-
ings) (Table S4).
Following the description of each policy participants
were asked, using a 6-point scale (“definitely no” to
“definitely yes”), if they would personally want to re-
ceive secondary findings. Participants were also asked
whether the proposed policy would be appropriate for
society as a whole. Participants were then asked wheth-
er they agreed or disagreed with the default and/or flex-
ibility of each policy.
Experience with and Knowledge of Genetics Participants
were asked about their previous experience with genet-
ics. The survey included 9 questions that tested key
genetic concepts explained in the informational brochure
participants received with Survey 1 (see Brochure S1).
These questions were asked to establish baseline and
sustained knowledge of basic concepts of genomic se-
quencing. Participants were also asked four subjective
knowledge questions (on a 5-point scale).
Information Needed to Inform a Decision to Undergo
Genomic Sequencing Participants selected how much and
what types of information they would want in order to feel
sufficiently informed before making a decision about
whether to undergo genomic sequencing. If participants
indicated that they wanted additional information about
the conditions being tested, they were then asked to select
what specific details they would want to know by checking
“all that apply” (see Survey S3). Participants also indicated
what sources of information (e.g., the internet; health care
provider) they would use to find out information to make a
decision.
Demographics Participants were asked to complete standard
demographic questions.
Survey 2: Post-deliberation assessment
Survey 2 included the same measures of attitudes towards
proposed policies, experience with and knowledge of genet-
ics, and information needs and sources used in Survey 1, as
well as a DD session evaluation.




Genetic and family history experience X X X
Changes to health/genetic testing X
Exposure to genetics in media X
Policy opinions
Personal & societal policy views X X X
Willingness to pay X X X
Risk assessment X X X
Knowledge and understanding
Genetics Concepts X X X
Definition of medically actionable X
Steps in genome sequencing X
Information Needs
Information needed for decision-making X X X
Sources for information X X X
Deliberation Evaluation
General satisfaction X
Change to understanding/attitudes X
Helpfulness for deciding on policies X
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DDSession Evaluation The DD session evaluation measured
general satisfaction with the DD session, whether the session
changed their understanding and/or attitudes about genomic
sequencing, how helpful the session was for answering policy
questions in the survey, and an open-ended question about
what they liked/disliked about the session.
Survey 3: Follow-up survey
Survey 3 included the same measures of attitudes toward pro-
posed policies, experience with and knowledge of genetics,
and information needs and sources used in Survey 1 and 2 (see
Survey S3).
Analyses
The participant characteristics of individuals with and without
a personal history of cancer were compared using independent-
samples t-tests for interval data variables and chi-square tests
for categorical variables. For policy preferences, we analyzed
responses on both the 6-point scale and as dichotomized ver-
sions (“agree” and “disagree”) with similar results. Here we
report the dichotomized versions of participant responses’ re-
garding policy preferences for ease of interpretation. We also
examined aggregate level policy preferences (grouping indi-
vidual level responses by assigned small group) for the three
proposed policies to see if there were any group level effects.
Within-subject responses across the three survey time
points were analyzed using paired-sample t-tests for inter-
val data and Cochran’s Q Test to determine any differences
on dichotomous dependent variables between the three sur-
vey time points. Analyses were conducted using SPSS
v.22.
Results
We posted information about our study on the website,
UMClinicalStudies.org. 265 people expressed interest in
participating in this study. Of those 265 interested
individuals, we invited 94 to participate based on a range of
demographic criteria (e.g., age, gender, ethnicity, personal
history of cancer). Ultimately, 76 invitees decided to enroll
in the study.
Surveys
Of the 76 participants enrolled in the study, 70 completed
Survey 1 (response rate = 92 Q), 66 attended the day-
long DD-session and completed Survey 2 (87 Q), and 64
DD session attendees completed follow-up Survey 3
(84 Q).
Demographics Of the 64 participants who attended the DD
session and completed all three surveys, 44 (68.8 Q) partici-
pants had a family history of cancer, as self-reported on
Survey 1, and 38 had a personal history of cancer, as
indicated in their UM Clinical Studies profile. The av-
erage age of participants was 57.3 (SD = 14), 70.3 Q were
female, and 21.9Q identified as being non-white. Participants





Age, Mean (SD) 57.3 (14)
Ethnicity (“mark all that apply”)
White 50 (78.1)
Black 11 (17.2)
American Indian or Alaskan Native 4 (6.3)
Asian 2 (3.1)
Hispanic 2 (3.1)
Middle Eastern/Arab 1 (1.6)
Other 1 (1.6)
Education
High school or less 4 (6.3)
Some college/college/trade school 33 (51.6)
Graduate degree 26 (40.6)




Below $40,000 16 (25.0)
$40,000–$79,999 28 (43.8)





Very good 19 (29.7)
Excellent 12 (18.8)
Had genetic testing ordered by a doctor
Yes 8 (12.5)
No 56 (87.5)
Have family history of…
Cancer 44 (68.8)
Heart disease 37 (57.8)
Neurological disorder 12 (18.8)
a Included are all participants who attended DD session and responded to
all three surveys. No significant differences between participants
with/without a personal history of cancer were detected
b Some percentages do not add to 100 because not all participants an-
swered the question
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tended to be highly educated, with 40.6 Q having a post-
bachelor’s degree (Table 3).
Experience with and Knowledge of Genetics The majority
(81.3Q) of respondents reported hearing of genomic sequenc-
ing prior to participating in the study. Eight (12.5Q) indicated
that they previously had genetic testing ordered by their doc-
tor. Participants correctly answered almost all of the 9 baseline
questions testing key genetic concepts in the informational
brochure (M = 8.0, SD = 1.0, range = 3–9), which was
reflected in the high self-reported confidence (M = 4.0,
SD = 0.8, range = 2–5) and understanding (M = 3.9,
SD = 0.9, range = 2–5) of genetic information. Despite this,
subjective and comparative knowledge of genetics were aver-
age (M = 3.1, SD = 1.0, range = 2–5 and M = 3.5, SD = 0.8,
range = 2–5) (Table S5).
Attitudes towards Proposed Policies Table 4 shows the
effect of deliberation on participant support for the pro-
posed policies for the return of secondary findings
across the 3 survey time points—including support for
the policy overall, the default (whether results are given
or not given), and the policy’s flexibility (whether there
is a choice). At baseline, an overwhelming majority
(89.1 Q) agreed with the proposed societal policy for
medically actionable results where patients are given
medically actionable results that are unrelated to the
reason for the sequencing, and they can ask to not be
given these results. For this policy, responses remained
unchanged ac r o s s a l l t h r e e su r v ey s (Χ 2 ( 2 ,
N = 62) = 1.412, p = 0.494). A minority (9.4 Q and
4.7 Q, respectively) of participants agreed at Survey 1
with the proposed policy for adult-onset conditions
where children and their parents are not given results
for adult-onset conditions unrelated to the reason for
the sequencing and are not given these results even if
they want them (9.4 Q for the policy overall), as well
as the policy for carrier status where patients are not
given carrier status results unrelated to the reason for
the sequencing and are not to be given these results
even if they want them (4.7 Q for the policy overall).
Across all three surveys, we detected a significant
change in the proportion of individuals that agreed with
both the policy on adult-onset disorders (Χ2 (2,
N = 62) = 13.300, p = 0.001) and carrier status (Χ2
(2, N = 60) = 11.375, p = 0.003). For example, agree-
ment with the adult-onset disorders policy increased
from 9.4 Q to 43.8 Q at the post-DD session assess-
ment, while agreement with the carrier status policy
increased from 4.7 Q to 21.9 Q.
Table 4 Effect of democratic deliberation on attitudes toward policies for secondary findings, n = 64a
Baseline (Survey 1) Post-DD session
(Survey 2)
Follow-up (Survey 3)
Proposed Policy Overall Default Choice Overall Default Choice Overall Default Choice
Medically actionable Patients are given medically actionable
results that are not related to the reason for the sequencing.
Patients have a choice: They can ask to NOT be given these
results.
QAgree 89.1 81.3 87.5 85.9 89.1 95.3 93.8 89.1 87.5
QDisagree 9.4 17.2 10.9 12.5 10.9 4.7 6.3 9.4 9.4
Adult-onset conditionsChildren and their parents are not given
results for adult-onset conditions that are not related to the
reason for the sequencing. Children and their parents have no
choice: They will not be given these results even if they want
them.
QAgree 9.4 20.3 7.8 43.8a 50.0a 31.3b 23.4a 39.1a 25.0b
QDisagree 87.5 76.6 89.1 54.7a 50.0a 68.8b 73.4a 57.8a 67.2b
Carrier status Patients are not given carrier status results that
are not related to the reason for the sequencing. Patients have
no choice: They will not be given these results even if they
want them.
QAgree 4.7 14.1 4.7 21.9a 31.3 15.6 7.8 23.4 6.3
QDisagree 98.4 84.4 93.8 75.0a 68.8 84.4 90.6 73.4 90.6
aP ≤ 0.01; The p value is based on related samples Cochran’s Q test, compared to baseline (Survey 1) response, adjusted for multiple comparison. Not all
participants answered the question
bP ≤ 0.05; The p value is based on related samples Cochran’s Q test, compared to baseline (Survey 1) response, adjusted for multiple comparison. Not all
participants answered the question
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Given the significant change in the proportion of individ-
uals that agreed with the policies on testing children for adult-
onset conditions and testing for carrier status across all three
surveys, pairwise multiple comparisons were examined by
applying Cochran’s Q test (adjusted for multiple compari-
sons). After the DD session (Survey 2), there was a significant
increase from baseline in the proportion of participants who
agreed with the overall proposed policy on returning second-
ary findings to parents and children for adult-onset conditions
(Χ2 (1, N = 62) = 3.560, p ≤ 0.001), the default part of the
policy (Χ2 (1, N = 60) = 3.935, p ≤ 0.001) and that they are not
given these results even if they want them (Χ2 (1,
N = 57) = 3.320, p = 0.003). There was also a significant
increase from baseline in the proportion of participants who
agreed with the proposed policy on carrier status, overall (Χ2
(1, N = 60) = 3.062, p = 0.007), but not the default or flexi-
bility portions. At follow-up (Survey 3), the increases in sup-
port for testing children for adult-onset conditions remained
statistically significant for the overall policy (Χ2 (1,
N = 60) = 2.465, p = 0.041), as well as the default (Χ2 (1,
N = 57) = 2.546, p = 0.033) and the no choice portions of the
policy (Χ2 (1, N = 57) = 2.554, p = 0.032). Views on the
proposed policy for carrier status results returned to baseline
at Survey 3, dropping from 21.9Q support to 7.8Q. Notably,
across all three surveys, a strong majority disagreed with the
“no choice” portion of the policies both for adult-onset con-
ditions (ranging from 67.2 Q to 89.1 Q) and carrier-status
(ranging from 84.4 Q to 93.8 Q).
Participants’ personal preferences for the return of
secondary findings mirrored the shifts in societal policy
preferences. However, it is worth noting that individ-
uals’ personal preferences did not perfectly map onto
their societal policy preferences. Across all three sur-
veys, anywhere from 8.0 Q–23.1 Q of the participants
had a policy preference that differed from their personal
preference. For example, nearly one-fourth of partici-
pants (23.1 Q) agreed with the proposed policy that
would not allow children and parents to be given results
for adult-onset conditions unrelated to the reason for
sequencing the child’s genome but said that they would
want to be told whether their child had an increased
risk of developing an adult-onset condition.
Information Needed to Inform the Decision to Undergo
Genomic Sequencing At Survey 1, 34 participants (53.1 Q)
indicated that they wanted detailed information about every
condition being tested before agreeing to have their genome
sequenced. Seventeen (26.6Q) responded that they wanted to
learn about all of specific types of “detailed information” that
we listed (Table S6). After the DD session (Survey 2), the
number of participants who indicated they wanted the detailed
information about every condition marginally decreased (from
53.1 Q to 39.4 Q), (Χ2 (1, N = 62) = 0.125, p = 0.264,
adjusted), but was significantly less (from 53.1 Q to 30.3 )
at follow-up (Χ2 (1, N = 62) = 0.219, p = 0.009, adjusted).
DD Session Evaluation Overall, participants had positive
views of the DD session. Participants felt their opinions were
respected, the process was fair, and they were willing to abide
by the policy decision put forth by the group (Table S7).
Participants also reported that attending the session increased
understanding about some of the outcomes that can occur as a
result of genomic sequencing (M = 4.5, SD = 0.6, range = 1–
5). Participants did not report a significant change in their
attitudes towards using genomic sequencing for medical pur-
poses (M = 3.9, SD = 0.9, range = 1–5).
Discussion
A significant ethical challenge of precision medicine is decid-
ing what to do with secondary findings from genomic se-
quencing. Policy options should be informed by public opin-
ion, but the complexity of genomic medicine makes it difficult
to learn what members of the public want done with these
findings. To address this challenge we used a proven method
of structured education and deliberation to inform citizens of
the complex scientific and ethical issues associated with sec-
ondary findings and to solicit their informed and considered
policy preferences.
Our study shows the limitations of relying on surveys alone
to measure public opinion about the disposition of secondary
findings. If policy makers were to use the results of our initial
survey (Survey 1) to determine the best approach for the return
of secondary findings, they would likely recommend that all
results be returned by default with a choice to opt out.
Although still in the minority, as we saw in Surveys 2 and 3,
education and deliberation altered the opinions of many par-
ticipants, making them more willing to consider an overall
policy where results are not returned by default with no opt-
in for adult-onset conditions in children and carrier status. The
deliberative session enhanced the public’s appreciation of the
complexities of genomic medicine and opened the door to
previously unconsidered and opposing viewpoints.
However, it should also be noted that many participants’
views at the one-month follow-up had reverted back to their
baseline preferences, perhaps suggesting that the effects of
deliberation may diminish over time if not supplemented by
further consideration of policy options.
Our study is also informative in two other respects. First,
we learned that participants were somewhat less concerned
about what the default policy was in terms of receiving/not
receiving secondary findings than with the preservation of a
choice to receive/not receive findings (e.g. flexibility of the
policy). This accounts for the differences between participant
attitudes toward the policy on medically actionable findings –
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which allowed for the choice to receive or refuse results – and
the other policies, which did not allow choice. The public
places a high value on choice, but this value was tempered
by education and deliberation, resulting in increased support
for policies that restricted choice and decreasing the desire for
detailed information about every condition being tested.
Further analysis of our qualitative data, including responses
to open ended survey questions and transcripts of the DD
sessions, will shed light on the underlying rationales behind
the public’s attitude toward the limits of choice. Second, we
learned that there is a difference between what people want for
themselves (to receive/not receive information) and what peo-
ple prefer as societal policy. Our data, in concert with other
research findings (Stone, Choi, de Bruin, & Mandel, 2013;
Ubel, Angott, & Zikmund-Fisher, 2011; Zikmund-Fisher,
Sarr, Fagerlin, & Ubel, 2006) indicate a sizeable minority of
people may have policy preferences that differ from their per-
sonal preferences, suggesting we cannot infer the public’s
support or opposition to genomic sequencing policies from
findings regarding only personal preferences.
Study Limitations
This was an exploratory study with the intent to help
shape national health policy on the disclosure of sec-
ondary genomic findings by soliciting informed public
opinion using a novel methodological approach. The
recruitment strategy was deliberately designed to maxi-
mize the likelihood of a diverse study sample, rather
than a sample representative of the population as a
whole; therefore, conclusions are not meant to be infer-
ential. Although there was high internal validity, the
external validity may be limited by the small self-
selected sample. For example, our population was high-
ly educated and, therefore, results may not be represen-
tative of more diverse populations. Given our short
(1 month) follow up time and limited sample size, larg-
er prospective, longitudinal studies to evaluate differ-
ences by subgroups are needed. While we were unable
to measure whether the education or the deliberation
component of the DD session was the mechanism re-
sponsible for the shift in participants’ perspectives, other
research using DD methodology found that education
alone does not account for shifts in perspective (Kim
et al., 2011). Given the complexity and novelty of both
the scientific and ethical issues that surround genomic
sequencing, it is also not surprising that there was some
shift back towards baseline in the 1 month follow-up
survey. The shift towards baseline responses could also
be due to a “recency effect”, in that they just partici-
pated in a day long education and deliberation session,
thereby biasing responses in favor of the policy on
Survey 2. The shift may also reflect an anchoring and
adjustment bias that has been observed in other health psychol-
ogy studies, whereby individuals may initially alter their beliefs
in response to new information (e.g., disease risk estimates),
only to have these beliefs drift back toward their initial “anchor-
ing” point over time. Similar results have been reported that
suggest the anchoring and adjustment bias exists across multi-
ple disease types and risk groups (Gurmankin, Domchek,
Stopfer, Fels, & Armstrong, 2005; Linnenbringer, Roberts,
Hiraki, Cupples, & Green, 2010; Weinstein et al., 2004).
Policy Implications and Research Recommendations
Our results may have significant policy implications given
that the value of secondary findings remains debatable.
While they are often of clinical significance, they also may
result in unintended psychological, social, and medical conse-
quences. Our study shows strong support for a policy where
medically actionable findings unrelated to the reason for se-
quencing are disclosed by default, and that patients have a
choice about whether they receive these results. We also show
there was little support for policies where results for adult-
onset conditions in children and carrier-status are not given
by default and there is no choice about disclosure. However,
as citizens become more informed and have discussions with
their fellow citizens they become significantly more support-
ive of these more restrictive policies. Translating levels of
public support into policy can be challenging. Nevertheless,
it may be useful for institutional review boards, other research
oversight bodies, and future policy-making panels to know
what happens when citizens are provided an opportunity to
learn and deliberate about the complex ethical and scientific
issues regarding of the return of secondary findings in geno-
mic sequencing.
Further, while our study was focused on preference for
policies regarding secondary findings, the results also reflect
the importance of pretest counseling since individual prefer-
ences seemed to change with deliberation.
Finally, our study also demonstrates the feasibility of a DD
approach for obtaining high quality feedback from the public
on policy issues that involve complex ethical and scientific
dimensions. Most importantly, this research confirms the need
to seek informed and considered public opinion about societal
policies on these complex disclosure issues.
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